Dr. Ballinger Shares Her Top News From ASCO 2024
Tarah Ballinger, MD, discusses what she considers to be the biggest developments from the 2024 ASCO Annual Meeting.
Breast cancer was a major area of development at this year's American Society of Clinical Oncology (ASCO) Annual Meeting. In particular, clinical trials of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (Enhertu; T-DXd) and sacituzumab govitecan (Trodelvy) offered significant insights into treatment options and sequencing for patients with breast cancer.
Tarah Ballinger, MD, is an associate professor of clinical medicine at Indiana University School of Medicine and the Vera Bradley Foundation Scholar in Breast Cancer Research, who specializes in breast medical oncology, shared her highlights from the 2024 ASCO Annual Meeting.
Transcription:
0:05 | I think in breast cancer this year, we're going to see a lot of updates from some of the different antibody-drug conjugates. I think these are great because there's going to be so many more options for our patients living with metastatic disease. The question and what I hope to hear in some of the discussions is how we're going to best sequence all of these different drugs so that we can ultimately improve outcomes for our patients.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
